Patient who received breast cancer vaccine as part of clinical trial speaks about experience
Chase Johnson, a 31-year-old woman diagnosed with triple-negative breast cancer, participated in a clinical trial for a breast cancer vaccine at Cleveland Clinic. The vaccine, developed by Anixa Biosciences, showed encouraging early results with every participant exhibiting an immune response and minor side effects.
A woman diagnosed with triple-negative breast cancer at 31 participated in a clinical trial for a breast cancer vaccine at Cleveland Clinic. The vaccine, developed by Anixa Biosciences, aims to treat and prevent breast cancer. Chase Johnson, the patient, was one of 35 participants in the first phase, which showed encouraging results with every participant exhibiting an immune response and minor side effects. The vaccine teaches white blood cells to identify cancer cells. The study is moving to phase two, involving up to 200 women, to measure safety and effectiveness. Johnson is now five years in remission.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.